Sir,

The combination of Metformin and Sulfonylurea is a well-studied therapy, which addresses both underlying defects of type 2 diabetes mellitus (T2DM) that is, insulin deficiency and insulin resistance.\[[@ref1]\]

Of the available low dose glimepiride (0.5 mg, 1 mg and 2 mg)\[[@ref2]\] based therapies, combinations with 1 mg and 2 mg of glimepiride and metformin are widely used and well accepted. Recently, we observed the effectiveness of glimepiride 0.5 mg and metformin 500 mg combination in 941 early stage T2DM patients who were followed up for a period of 3 months. There was a 24.5% reduction in fasting blood glucose (baseline: 151 mg/dl, after 3 months: 114 mg/dl), 26.5% reduction in postprandial blood glucose (baseline: 215 mg/dl, after 3 months: 158 mg/dl) and 28.2% reduction in random blood glucose (baseline: 202 mg/dl, after 3 months: 145 mg/dl). The therapy was well-tolerated, and there were no reports of hypoglycemia or weight gain.

This observation is in concordant with earlier studies that low-dose metformin-sulfonylurea combination therapy achieved a good glycemic control, caused least hypoglycemia, weight gain and gastrointestinal disturbances.\[[@ref3]\] Thus, initiating a therapy with a combination of glimepiride 0.5 mg and metformin 500 mg can be considered suitable for the management of early stage type 2 diabetic patients, which however needs to be substantiated in future by large-scale randomized studies.
